Mukut Gohain
| Mukut Gohain | |
|---|---|
| Born | 1975 Tinsukia, Assam, India |
| 🎓 Alma mater | Universidad de Burgos (Post PhD)[1] |
| 💼 Occupation |
|
| Known for | Co-inventor of "Enmetazobactam" – the first Indian US FDA-approved new drug invented in India (Exblifep) |
| 👩 Spouse(s) | Dr. Sangeeta Baruah Gohain |
Mukut Gohain is an Indian pharmaceutical scientist from Assam, currently serving as a senior scientist at Chemical Process Technologies (Pty) Ltd in South Africa.[2] He is noted for his role in the discovery of Enmetazobactam, a novel β-lactamase inhibitor antibiotic that received approval from the United States Food and Drug Administration (US-FDA). The European Medicines Agency (EMA) has also recognized this antibiotic for the treatment of UTIs and pneumonia.[3]
Early life and education
Mukut Gohain was born in Tinsukia, Assam, India, in 1975. He completed his Bachelor of Science (B.Sc.) in Chemistry in 1997 from Dibrugarh University and earned his Master of Science (M.Sc.) in Chemistry in 2000 from Assam University, Silchar. After completing his M.Sc., he joined the Medicinal Chemistry Division of the Regional Research Laboratory (CSIR) in Jorhat to pursue a Ph.D. under the guidance of Dr. J. S. Sandhu, FNA.[4]
Career
Dr. Mukut Gohain currently serves as principal investigator and head of the Research and Development Department at Chemical Process Technologies (Pty) Ltd in South Africa.[5] He led a research team with Sanmar Specialty Chemicals Limited and Orchid Pharma (Chennai) which successfully developed the antibiotic Enmetazobactam.[6] This β‑lactamase inhibitor represents the first antibiotic developed in India to receive approval from the United States Food and Drug Administration (US‑FDA).[7] Enmetazobactam emerged from a lengthy, complex drug‑development process and is considered an impactful advancement in antibacterial therapy against a broad range of pathogens causing urinary tract infections, pneumonia, etc. Later, the Drug was approved by Drugs Controller General of India (DCGI) to manufacture and market its new chemical entity (NCE).[8][9]
Award and Recognition
Dr. Mukut Gohain has been honored with the Excellence in Science & Innovation Award for his contributions to science by Sadin Pratidin group in their annual Sadin-Pratidin Achiever Awards Distribution.[10]
Sources
- ↑ "Collaboration with Estela Álvarez Manuel". Universidad de Burgos Research Portal. Universidad de Burgos. Retrieved 2025-07-20.
- ↑ "Mukut Gohain". ResearchGate. Retrieved 2025-07-19.
- ↑ "Assam scientist elated as Enmetazobactam gets US FDA's approval". The Times of India. 2024-02-28. Retrieved 2025-07-19.
- ↑ "Synthesis of novel pyrrolo[1,2-a]quinoxalin-4(5H)-ones as potential antimicrobial agents". ScienceDirect. Elsevier. doi:10.1016/j.tet.2003.10.075. Retrieved 2025-07-19.
- ↑ "Assam scientist elated as Enmetazobactam gets US FDA's approval". The Times of India. 2024-02-28. Retrieved 2025-07-19.
- ↑ "Dr Mukut Gohain's Enmetazobactam has been finally approved". News18 Assam. Network18 Media & Investments Ltd. 2024-02-29. Retrieved 2025-07-20.
- ↑ "Assamese scientist Dr Mukut Gohain develops 1st Indian antibiotic approved by FDA". ETV Bharat. 2024-02-27. Retrieved 2025-07-20.
- ↑ "India's DCGI approves Orchid Pharma's API Enmetazobactam". Pharmaceutical Technology. PT Staff. 2024-06-06. Retrieved 2025-07-19.
- ↑ Bora, Hemanta (2024-12-31). "Title of the Article". Asomiya Pratidin. Guwahati, Assam: Asomiya Pratidin.
- ↑ "In Photos – Sadin‑Pratidin Achiever Awards 2024". Pratidin Time. 2024-XX-XX. Retrieved 2025-07-19. Check date values in:
|date=(help)
This article "Mukut Gohain" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Mukut Gohain. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
